Complete Mounjaro versus Wegovy Cost Analysis
Mounjaro versus Wegovy Monthly Cost Structure Explained
Understanding the Mounjaro versus Wegovy monthly cost comparison requires examining both medications' unique dosing schedules and pricing tiers. Wegovy follows a 16-week escalation protocol starting at 0.25mg, progressing through 0.5mg, 1mg, and 1.7mg before reaching the 2.4mg maintenance dose. Monthly costs begin at £79.99 for the starter dose, increasing gradually to £209.99 for maintenance dosing. This structured approach allows patients to budget progressively, with the highest costs occurring only after establishing treatment tolerance.
Mounjaro utilises a different escalation pattern with tirzepatide, starting at 2.5mg and potentially increasing to 15mg depending on clinical response. The dual GIP and GLP-1 receptor agonist mechanism of Mounjaro creates a distinct pricing structure compared to Wegovy's single GLP-1 approach. Both medications represent significant monthly investments, but the cost trajectories differ substantially. The Mounjaro versus Wegovy decision often hinges on these long-term financial commitments alongside clinical considerations.
Detailed Wegovy Pricing Structure and Bundle Savings
Our transparent Wegovy pricing eliminates surprises during your weight management journey. The escalation phase costs are: £79.99 monthly (0.25mg weeks 1-4), £94.99 monthly (0.5mg weeks 5-8), £99.99 monthly (1mg weeks 9-12), £139.99 monthly (1.7mg weeks 13-16), and £209.99 monthly for 2.4mg maintenance dosing. New customers benefit from the FIRST40 discount code, while returning patients use DOSE25 to maintain competitive pricing. Our Getting Started bundles provide treatment continuity: the Intro Duo (0.25mg & 0.5mg) costs £169.99, covering your first 8 weeks.
Bundle pricing offers convenience rather than significant savings, with options like the Progress Trio (0.5mg, 1mg & 1.7mg) at £369.99 covering 12 weeks of mid-escalation treatment. The Ultimate Stability Trio provides three months of 2.4mg maintenance dosing for £649.99, ensuring uninterrupted treatment at the therapeutic dose. When comparing Mounjaro versus Wegovy monthly costs, these bundle options reduce ordering frequency and provide supply security, particularly valuable during periods of medication shortages.
Clinical Evidence Supporting Mounjaro versus Wegovy Investment
The STEP clinical trial programme demonstrated Wegovy's effectiveness, with patients achieving approximately 15% average weight loss at 68 weeks when combined with reduced-calorie diet and increased physical activity (Wilding et al., NEJM, 2021). STEP 1 showed sustained results, while STEP 5 confirmed approximately clinically studied weight loss maintained at 2 years. The SELECT cardiovascular outcomes trial revealed a 20% reduction in major cardiovascular events, adding clinical value beyond weight management.
Mounjaro's clinical evidence stems from the SURMOUNT trial programme, evaluating tirzepatide's dual GIP and GLP-1 receptor agonist mechanism. When considering Mounjaro versus Wegovy monthly costs, the clinical evidence base helps justify the ongoing investment required for either medication. Both treatments require long-term commitment, making the monthly cost analysis crucial for treatment adherence and success.
How Wegovy's GLP-1 Mechanism Justifies Monthly Investment
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics natural incretin hormones regulating appetite and glucose metabolism. The medication works by binding to GLP-1 receptors in the brain's appetite centres, reducing hunger signals and promoting satiety after smaller meals. This mechanism may also slow gastric emptying, extending the feeling of fullness between meals. Unlike quick-fix approaches, Wegovy's hormonal regulation provides sustainable appetite control, justifying the monthly investment through its evidence-based biological approach. The once-weekly FlexTouch pen injection delivers consistent medication levels, maintaining therapeutic effect throughout the dosing interval.
Streamlined Ordering Process for Ongoing Monthly Treatment
EverydayMeds simplifies ongoing Mounjaro versus Wegovy access through our efficient prescribing process. The 3-minute online clinical assessment captures your medical history, current medications, and weight management goals. Our qualified prescribers review applications within 3 working days (or 24 hours with express service), ensuring clinical appropriateness before dispensing. Once approved, next-day delivery utilises cold-chain temperature control, maintaining medication integrity from our GPhC-registered pharmacy (#9012878) to your doorstep. This streamlined approach reduces treatment interruptions that could compromise your weight management progress. Automated reorder reminders help maintain consistent dosing schedules essential for both Wegovy and Mounjaro effectiveness.
Storage Requirements Affecting Long-term Costs
Proper storage protects your monthly medication investment and ensures therapeutic effectiveness. Wegovy requires refrigeration at 2-8°C before first use, but offers superior travel flexibility with 6 weeks room temperature stability below 30°C once removed from the fridge. This advantage over Mounjaro's 21-day room temperature limit reduces medication waste during holidays or business travel. The FlexTouch pen design withstands normal handling, reducing replacement costs from accidental damage. Understanding these practical considerations helps optimise your Mounjaro versus Wegovy monthly investment. Each pen contains four doses, lasting exactly four weeks when used as prescribed, allowing accurate monthly budgeting.
Annual Cost Projection for Mounjaro versus Wegovy Treatment
Long-term financial planning requires understanding the annual cost trajectory for both medications. Wegovy's first year includes 16 weeks of dose escalation (approximately £1,740) followed by 36 weeks of maintenance dosing at £209.99 monthly (approximately £1,950), totalling roughly £3,690 annually. Subsequent years cost approximately £2,735 annually at maintenance dosing, with DOSE25 discount code providing ongoing savings for returning customers. These projections assume consistent dosing without treatment interruptions or dose adjustments.
When evaluating Mounjaro versus Wegovy annual costs, consider that weight management requires sustained commitment, with clinical trials showing weight regain following treatment discontinuation. The investment extends beyond medication costs to include dietary modifications, increased physical activity, and potential healthcare monitoring. Both medications represent substantial annual expenditures, making the monthly cost comparison crucial for treatment sustainability and adherence.
Secure Your Mounjaro versus Wegovy Treatment Today
Ready to begin your weight management journey with transparent, predictable monthly costs? EverydayMeds offers both Wegovy and Mounjaro through our secure, regulated platform, with pricing clarity from treatment initiation through maintenance dosing. New customers use discount code FIRST40, while returning patients benefit from DOSE25 for ongoing affordability. Our clinical team provides personalised guidance on the Mounjaro versus Wegovy decision based on your individual circumstances, medical history, and budget considerations. Visit https://everydaymeds.co.uk/collections/wegovy to start your clinical assessment and secure next-day delivery of your chosen treatment. Take control of your weight management investment with the UK's trusted online pharmacy, GPhC #9012878.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
